RxDoctor Payments Data

Puneet Raman, MD

Hematology & Oncology · Chicago, ILNPI 1659909612

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,044 of the $1,466 with a category attached, or 71.2%. It is spread thinly across 11 manufacturers, the largest accounting for just 23.2%. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.

$1,466in general payments, 2019–2025

Across 21 payments — averaging $69.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$340
  • Daiichi Sankyo Inc.$200
  • Adaptive Biotechnologies Corporation$188
  • Incyte Corporation$170
  • Janssen Scientific Affairs, LLC$141
  • AbbVie$125
  • plus $302 from 5 others

What the payments were for

  • Food & beverage$1,04471%
  • Education$42229%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,466 in reported general payments places this provider in the 40th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024
$7,489
Medicare patients
49
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$6,928

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →